Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants
26 October 2016 - 8:15AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today
announced that it intends to offer shares of its common stock and
warrants to purchase common stock in an underwritten public
offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Dawson James Securities, Inc. is acting as the
sole book-running manager for the offering. Tonix expects to use
the net proceeds of the offering to support the continued
development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets)
for the treatment of posttraumatic stress disorder (PTSD),
including completion of the first interim analysis in the phase 3
study in military-related PTSD, to further develop other pipeline
programs, for working capital and other general corporate purposes,
and possibly acquisitions of other companies, products or
technologies, though no such acquisitions are currently
contemplated.
The securities described above are being offered
by Tonix pursuant to a shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission (SEC)
and subsequently declared effective on August 15, 2014. A
preliminary prospectus supplement relating to the offering is being
filed with the SEC and, once filed, will be available on the SEC's
website at http://www.sec.gov.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Copies of the preliminary prospectus supplement
and accompanying base prospectus relating to the offering may be
obtained from Dawson James Securities, Inc., Attention: Prospectus
Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL
33432, mmaclaren@dawsonjames.com or toll free at (866)
928-0928.
About Tonix Pharmaceuticals Holding
Corp.
Tonix is developing next-generation medicines
for common disorders of the central nervous system, with its lead
program focusing on posttraumatic stress disorder. This disorder is
characterized by chronic disability, inadequate treatment options,
high utilization of healthcare services, and significant economic
burden. This press release and further information about Tonix can
be found at www.tonixpharma.com.
Safe Harbor / Forward-Looking
Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. Forward-looking statements include Tonix’s ability to
conduct and complete a public offering of its securities (including
the anticipated size and closing date of the offering). These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval
and commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2015, as filed
with the Securities and Exchange Commission (the “SEC”) on March 3,
2016, and future periodic reports filed with the SEC on or after
the date hereof. All of Tonix's forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date hereof.
Contacts:
Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185
Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035
MSLGROUP Boston (media)
Sherry Feldberg
tonix@mslgroup.com
(781) 684-0770
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024